GSK was trying to revive a product pulled from US markets in 2022. Its shares fell 4.6 per cent, or 65p, to 1348p.

Health-care companies fell as traders hedged their bets on the outlook for growth in the sector. Insurers, including Elevance, which recently warned of cost pressures from its Affordable Care Act ...